Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.
about
Insights into human immunodeficiency virus-hepatitis B virus co-infection in IndiaNew loci associated with chronic hepatitis B virus infection in Han ChineseImpaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfectionNo increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.Predictors of loss of hepatitis B surface antigen in HIV-infected patientsCoinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen.TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B.Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected PatientsInterleukin-21 gene polymorphisms and chronic hepatitis B infection in a Chinese population.Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconvertersReversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patientsImmunopathogenesis of hepatitis B virus infection.Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection.Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liverHost ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire.HIV and co-infections.Hepatitis B virus (HBV)-specific T-cell responses to recombinant HBV core protein in patients with normal liver function and co-infected with chronic HBV and human immunodeficiency virus 1 (HIV-1)Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective.Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.Immune restoration diseases reflect diverse immunopathological mechanisms.Future directions in the treatment of HIV-HBV coinfection.The Predominant CD4+ Th1 Cytokine Elicited to Chlamydia trachomatis Infection in Women Is Tumor Necrosis Factor Alpha and Not Interferon Gamma.HBV-Specific Adaptive Immunity.DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques.HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity.Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis.Cytotoxic T lymphocytes and CD4 epitope mutations in the pre-core/core region of hepatitis B virus in chronic hepatitis B carriers in Northeast Iran.T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use.Hepatitis B e Antigen Seroconversion Is Related with the Function of Dendritic Cells in Chronic Hepatitis B Virus Infection.First hepatitis B virus full-length genomic study among blood donors from Argentina: unexpected mutations in the circulating subgenotypes' proteins.HLA-DP and γ-interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection.Association of the rs3077 and rs9277535 polymorphisms in HLA-DP with hepatitis B virus infection and spontaneous clearance: a meta-analysis.Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development.The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection.
P2860
Q26797826-D6FFB5FC-0D87-4596-9EB7-8C736698690CQ28300932-739717E3-40BA-491F-A4C5-1988957CDF6CQ33449162-78F6B033-0E76-414D-8963-BBB1513176CAQ33676594-A1162894-B64C-44CF-BC16-3717ECB57413Q33716290-71C4BB74-D807-4B41-962E-0D73860E1CD4Q33877464-EF4C72C4-333A-44D4-AB9E-8CEA99690896Q35097411-2FD7246E-100E-4330-BA4D-2540D3B60F21Q35200503-1446C631-A394-4F68-89BB-7BB1E21FB6ABQ35375495-EB6B85B0-F975-490C-9808-D4232D30472DQ35628651-1D515121-2E36-43F9-9F0A-7D7FE15CAFEAQ36302694-67B96455-84BA-482D-961D-7473EFD56F93Q36666336-AEEC7DD1-B67A-4C85-A642-21080538AD64Q36853435-50410D8C-7DD1-438C-9267-1AA7ADED241DQ36871557-5D2A7DA2-844F-44F9-83ED-E7C94B486B45Q36949834-D9397EDC-C7E1-423D-9B69-236FF54C66C4Q36970184-AB9EEB1B-D1C9-4B29-9018-49501D31C181Q37033272-F407B8F1-7FED-4CA7-B43A-CEDE6BA9A346Q37195244-DF483463-513D-43AF-A067-2A96C1B4FFE4Q37287635-E6041E94-BA07-40DE-97FB-2844DD8CB5B5Q37409995-39155741-59A3-423C-A0BF-449005C300E9Q37439933-C6ED60B5-2B17-453E-9479-606DA30B100CQ37835132-572F59E3-2E8A-45AE-9052-EC23863A6D1CQ38613247-31B5FA47-3DC1-406A-99AD-DA4F6635861AQ39047929-4B2F5A96-EFB7-462F-8F71-35DACFBADC2AQ39244731-CDEDE3AE-D57D-4668-BF16-6652D06229CAQ39758143-0A4A1161-0500-4581-A530-8E2EFBD3D4DEQ40109585-3192C1DD-3404-424B-9EB7-C21C327F82E2Q40562116-34E9AC98-41A4-4842-B31E-05505C02DF2FQ41553681-A052CA81-1966-4F92-9FFE-8A53B0FD0868Q41583437-2EDEE521-E8CB-4BF8-AFF5-101BB98A7801Q42274001-AEAB6621-9D72-40EA-A396-27A83326CB02Q43756926-D1D0FBBE-E0F1-4693-94F1-04A7F77F5B81Q45361545-097629A5-B477-4E69-8720-A27F3A914AA7Q45399784-2D743FE9-DA56-467B-B9CD-DA050DB0AD0E
P2860
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Reduced hepatitis B virus (HBV ...... active antiretroviral therapy.
@ast
Reduced hepatitis B virus (HBV ...... active antiretroviral therapy.
@en
type
label
Reduced hepatitis B virus (HBV ...... active antiretroviral therapy.
@ast
Reduced hepatitis B virus (HBV ...... active antiretroviral therapy.
@en
prefLabel
Reduced hepatitis B virus (HBV ...... active antiretroviral therapy.
@ast
Reduced hepatitis B virus (HBV ...... active antiretroviral therapy.
@en
P2093
P2860
P50
P1433
P1476
Reduced hepatitis B virus (HBV ...... active antiretroviral therapy.
@en
P2093
Angeline Bartholomeusz
Anna Ayres
J Judy Chang
Joseph Sasadeusz
P2860
P304
P356
10.1128/JVI.79.5.3038-3051.2005
P577
2005-03-01T00:00:00Z